Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : FDA Panel to Vote on Pfizer COVID-19 Shots for Kids; Data Shows Vaccine 90.7% Effective in Children Aged 5 to 11

10/22/2021 | 11:27am EST


© MT Newswires 2021
All news about PFIZER, INC.
12/03FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
RE
12/03Health Care Ticks Lower As Pfizer Gains - Health Care Roundup
DJ
12/03PFIZER : FDA Issues Update to XELJANZ® Prescribing Information in the United States
PU
12/03U.S. administers 466.3 mln doses of COVID-19 vaccines - CDC
RE
12/03Merck to supply up to 1 mln courses of COVID-19 pill to Canada
RE
12/03Canada Signs Deal for 1 Mln Doses of Pfizer Covid Antiviral and 500K Merck's Covid Pill
MT
12/03Vaccine makers could make Omicron-specific booster, says Fauci
RE
12/03BioNTech Capable of Quickly Modifying Vaccine for Omicron Variant, CEO Says
MT
12/03BioNTech CEO Expects To Modify COVID-19 Vaccine To Omicron Variant
MT
12/03Malaysia Confirms First Case of New COVID-19 Variant
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 517 M - -
Net income 2021 21 354 M - -
Net Debt 2021 27 873 M - -
P/E ratio 2021 14,0x
Yield 2021 2,91%
Capitalization 305 B 305 B -
EV / Sales 2021 4,08x
EV / Sales 2022 3,84x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 54,27 $
Average target price 49,58 $
Spread / Average Target -8,65%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.44.09%304 610
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641
ABBVIE INC.8.18%210 113